ACP Access Masterclass Update - March 2026
GLPs, HRT and Progesterone + FDA Black Box Updates
What are the updates?
Female: Key milestones leading to FDA label changes in February 2026 and evolving evidence on risks and benefits
PDF Download: Female - Key milestones leading to FDA label changes in February 2026 and evolving evidence on risks and benefits
Male - Key milestones leading to FDA label changes in February 2026 and evolving evidence on risks and benefits
PDF Download: Male - Key milestones leading to FDA label changes in February 2026 and evolving evidence on risks and benefits
A Clinical Guide for Providers: Use of Incretin Therapies (GLP-1s) for Women on HRT with Progesterone guidance.
PDF Download: A Clinical Guide for Providers: Use of Incretin Therapies (GLP-1s) for Women on HRT with Progesterone guidance.
Reference: British Menopause Society - Use of incretin-based therapies in women using HRT